Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 19339 [2014-07776]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 67 / Tuesday, April 8, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2014–0003]
Draft Guideline—Centers for Disease
Control and Prevention Draft Guideline
for the Prevention of Surgical Site
Infections
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (DHHS).
ACTION: Reopening of public comment
period.
AGENCY:
On January 29, 2014 the
Centers for Disease Control and
Prevention (CDC), located within the
Department of Health and Human
Services (HHS) published a notice in the
Federal Register requesting public
comment on the Draft Guideline for the
Prevention of Surgical Site Infections
(SSIs) (draft Guideline) (79 FR 4724).
Written comments were to be received
on or before February 28, 2014. Some
commenters requested additional time
to review the guideline and provide
comments. In consideration of these
requests, HHS/CDC is reopening the
comment period for 30 days.
DATES: Comments must be received on
or before May 8, 2014.
ADDRESSES: You may submit comments,
identified by CDC–2014–0003, by any of
the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Division of Healthcare Quality
Promotion, National Center for
Emerging and Zoonotic Infectious
Diseases, Centers for Disease Control
and Prevention, Attn: Guideline for the
Prevention of Surgical Site Infections
Docket No. CDC–2014–0003, 1600
Clifton Rd. NE., Mailstop A07, Atlanta,
Georgia, 30333.
Instructions: All submissions received
must include the agency name and
docket number or RIN. All relevant
public comments received will be
posted publicly to www.regulations.gov
without change, including any personal
or proprietary information provided. To
download an electronic version of the
draft Guideline and appendices, access
https://www.regulations.gov.
Written materials identified by Docket
No. CDC–2014–0003 will be available
for public inspection Monday through
Friday, except for legal holidays, 9 a.m.
until 4:30 p.m. Eastern Standard Time,
at CDC Library, 1600 Clifton Road NE.,
Atlanta, Georgia, 30333. Please call
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:42 Apr 07, 2014
Jkt 232001
19339
ahead to (404) 639–1717 and request a
Library representative schedule your
visit. All public comments will be
reviewed and considered prior to
finalizing the draft Guideline.
FOR FURTHER INFORMATION CONTACT: Erin
Stone, Division of Healthcare Quality
Promotion, National Center for
Emerging and Zoonotic Infectious
Diseases, Centers for Disease Control
and Prevention, 1600 Clifton Road NE.,
Mailstop A–31, Atlanta, Georgia, 30333;
Telephone: (404) 639–4000.
SUPPLEMENTARY INFORMATION: The draft
Guideline addresses new and updated
strategies for the prevention of SSI in
healthcare settings. This draft Guideline
can be found at https://
www.regulations.gov Docket No. CDC–
2014–0003.
CDC also published the supporting
appendices that include primary
evidence, study evaluation, and data
evaluation tables that were used in
developing the draft Guideline
recommendations.
The draft Guideline is designed for
use by infection prevention staff,
healthcare epidemiologists,
administrators, nurses, and personnel
responsible for developing,
implementing, and evaluating infection
prevention and control programs for
healthcare settings across the
continuum of care. The
recommendations contained in the draft
Guideline are based on a targeted
systematic review of the best available
evidence for specific topics related to
the prevention of surgical site infections
(SSI).
Since 2010 CDC has collaborated with
national partners, academicians, public
and private health professionals, and
other partners to create this draft
Guideline. Additionally, CDC sought
input in each phase of development
from subject matter experts in surgery,
infectious diseases, and orthopedics
through a Guideline Expert Panel
formed to develop the new draft
Guideline. CDC also received input from
the Healthcare Infection Control
Practices Advisory Committee (HICPAC)
throughout the development of the draft
Guideline. HICPAC includes
representatives from public health,
infectious diseases, regulatory and other
federal agencies, professional societies,
and other stakeholders. This new draft
Guideline will not be a federal rule or
regulation.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: April 3, 2014.
Ron A. Otten,
Acting Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–07783 Filed 4–7–14; 8:45 am]
[FR Doc. 2014–07776 Filed 4–7–14; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
PO 00000
Frm 00024
Fmt 4703
Sfmt 9990
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Surveillance and Research of
Muscular Dystrophies and
Neuromuscular Disorders, FOA DD14–
001, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Times and Dates:
9:00 a.m.–6:00 p.m., April 22, 2014
(Closed)
9:00 a.m.–6:00 p.m., April 23, 2014
(Closed)
9:00 a.m.–6:00 p.m., April 24, 2014
(Closed)
Place: Teleconference
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters For Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Surveillance and Research of Muscular
Dystrophies and Neuromuscular
Disorders, FOA DD14–001, initial
review.’’
Contact Person For More Information:
M. Chris Langub, Ph.D., Scientific
Review Officer, CDC, 4770 Buford
Highway NE., Mailstop F–80, Atlanta,
Georgia 30341, Telephone: (770) 488–
3585, EEO6@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
E:\FR\FM\08APN1.SGM
08APN1
]]>Agencies
[Federal Register Volume 79, Number 67 (Tuesday, April 8, 2014)]
[Notices]
[Page 19339]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07776]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns Surveillance and Research of
Muscular Dystrophies and Neuromuscular Disorders, FOA DD14-001, initial
review.
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Times and Dates:
9:00 a.m.-6:00 p.m., April 22, 2014 (Closed)
9:00 a.m.-6:00 p.m., April 23, 2014 (Closed)
9:00 a.m.-6:00 p.m., April 24, 2014 (Closed)
Place: Teleconference
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the Determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters For Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Surveillance and Research of Muscular Dystrophies and
Neuromuscular Disorders, FOA DD14-001, initial review.''
Contact Person For More Information: M. Chris Langub, Ph.D.,
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F-80,
Atlanta, Georgia 30341, Telephone: (770) 488-3585, EEO6@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2014-07776 Filed 4-7-14; 8:45 am]
BILLING CODE 4163-18-P
